Ототоксический эффект цитостатических препаратов, содержащих платину

Abstract

Ototoxicity refers to the hearing impairment that results from the temporary or permanent inner ear dysfunction after treatment with an ototoxic drug. Other drug classes known to have ototoxic properties include aminoglycosides, loop diuretics, quinine, nonsteroidal anti-inflammatory drugs, and antiretroviral therapy. Platinum-based chemotherapy drugs are effective drugs used to treat many types of malignant neoplasms. However, its ototoxic potential puts cancer patients at risk of hearing loss. This, in turn, negatively affects the patient’s quality of life. It is essential for clinicians working with these patients to be aware of the ototoxic properties of platinum preparations and the clinical signs in order to identify patients at risk of developing hearing loss. The review identified peer-reviewed articles available from January 1975 to July 2019 on the monitoring of cytotopic toxicity and ototoxicity associated with cisplatin, and included only articles in English. The same researcher conducted a literature search and reviewed abstracts and articles for inclusion in the study. The studies were identified using a MeSH (Medical Subject Headings) keyword and term search in electronic databases. A manual search for relevant authors and journals was also completed. The links cited by each publication, review, or book chapter were reviewed to find additional potential publications. This article provides an updated review of the ototoxicity associated with platinum-based chemotherapy drugs.